Compare iShares MSCI China ETF (MCHI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI China ETF trades at $52.55 (market cap $5.94B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: iShares MSCI China ETF is far larger — about 2.8× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| MCHI | RXRX | |
|---|---|---|
Market Cap | $5.94B | $2.14B |
Volume | 1,575,471 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $6.79 |
52-Week Low | $50.48 | $2.84 |
Typical Hold Time | 63 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $51.36, down 0.54% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption, though some indicators like the 12-day RSI suggest potential oversold conditions. Recent news highlights trade tensions and policy uncertainty ahead of key US-China meetings.
While MCHI trades at historical discounts to US indices according to Seeking Alpha (2026-08-10), the bearish technical setup and China's macroeconomic risks create near-term pressure. Potential catalysts include progress in trade talks and corporate profit growth, but investors face significant exposure to China's regulatory environment and global trade dynamics.
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
